SCHEMBL4502144

SCHEMBL4502144

O=C(O)C1CNCC(NS(=O)(=O)c2ccc(-c3ccccc3)cc2)C1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
REN P00797 4/20 0.57
SLC6A11 P48066 1/20 0.52
MMP9 P14780 6/20 0.49
CA12 O43570 5/20 0.49
MMP2 P08253 5/20 0.49
CA9 Q16790 3/20 0.49
TSHR P16473 1/20 0.48
ALDH1A1 P00352 1/20 0.48
CA2 P00918 4/20 0.47
CA1 P00915 2/20 0.47
UCHL1 P09936 3/20 0.45
USP30 Q70CQ3 3/20 0.45
MMP1 P03956 2/20 0.44
MMP3 P08254 1/20 0.44
MMP13 P45452 1/20 0.44
MMP14 P50281 1/20 0.44
GAA P10253 1/20 0.43
MMP12 P39900 1/20 0.43
IKBKB O14920 1/20 0.43
CHUK O15111 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4502147 1.00 REN (0.57) RENSLC6A11MMP9CA12MMP2
SCHEMBL4508093 0.92 REN (0.59) RENSLC6A11MMP9MMP2TSHR
SCHEMBL4508089 0.92 REN (0.59) RENSLC6A11MMP9MMP2TSHR
SCHEMBL4499196 0.86 MMP2 (0.58) RENMMP9MMP2TSHRALDH1A1
SCHEMBL4499198 0.86 MMP2 (0.58) RENMMP9MMP2TSHRALDH1A1
SCHEMBL4514576 0.85 REN (0.53) RENSLC6A11MMP9MMP2TSHR
SCHEMBL4493886 0.85 REN (0.56) RENMMP9CA12MMP2TSHR
SCHEMBL4491241 0.85 REN (0.68) RENTSHRALDH1A1CA2CA1
SCHEMBL4514580 0.85 REN (0.53) RENSLC6A11MMP9MMP2TSHR
SCHEMBL4494687 0.85 REN (0.68) RENTSHRALDH1A1CA2CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090233920-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-09-17 US claimed
EP-1907359-A2 3,5-SUBSTITUTED PIPERIDINE DERIVATIVES EFFECTIVE ON RENIN-RELATED DISORDERS Novartis AG (CH) 2008-04-09 EP claimed
WO-2007006534-A2 PIPERIDINE DERIVATIVES USEFUL IN THE DIAGNOSTIC AND THERAPEUTIC TREATMENT OF DISEASES DEPENDING ON RENIN ACTIVITY NOVARTIS AG (CH) 2007-01-18 WO claimed
US-20090233920-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233920-A1 ORGANIC COMPOUNDS REN, ACE, AGTR1 REN 1/4885SLC6A11 1122/4885MMP9 693/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.